Carl Whatley leads Vitruvias with expert knowledge of all facets of the generic pharmaceutical drug industry. His leadership background coupled with a passion to expand the generic drug market have led to the development of multiple successful companies bringing next generation drugs into American pharmacies.

• 35 year veteran in the pharmaceutical industry
• Formed Cendalor LLC in 2009, a boutique management consulting and investment analysis firm serving the pharmaceutical, medical food, and dietary supplement sectors.
• Served as Chief Executive Officer of Kowa Company Limited, which acquired ProEthic.
• Co-founded ProEthic Laboratories, LLC and Midlothian Laboratories. In under 5 years, the combined companies were generating top-line revenue of almost $40 million.
• Spent 20 years in various pharmaceutical divisions of American Home Products Corporation, which included Ives Laboratories, Ayerst Laboratories, and Wyeth Laboratories. Won several national sales awards including the Presidents Golden Circle and the Gala Award for outstanding performance.
• Authored “Getting Under the Skin” by C. Whatley, Pharmaceutical Formulation & Quality
• Featured a 2008 edition of “PharmaVoice Magazine” as part of the “100 of the Most Inspiring People of the Year” within the Pharmaceutical Industry
• Small Business Administration’s Business “Person of the Year” for the State of Alabama in 2006
• Selected as a finalist for Ernst & Young “Entrepreneur of the Year Award” in 2005 and 2006
• Co-holder and co-inventor of three patents
• Chairman of the Board of E.A.T. South, a nonprofit that encourages healthy lifestyles through education and sustainable food production.
• Chairman of the Auburn University at Montgomery Capital Campaign and Chair of the Auburn University at Montgomery Chancellors Advisory Board
• B.A. from Auburn University at Montgomery, selected as a “Top 40 Alumni” in 2010

Bryce Harvey leads Vitruvias as Vice Manager, Co-Founder and Director. With decades of experience at Johnson & Johnson and successful growth of two companies prior to Vitruvias, Bryce is a seasoned industry leader with an acute sense for business development and key partnerships.

• 35 year veteran in the pharmaceutical industry
• Founded H2-Pharma in 2013, a company that focuses on the research and development of niche generic drug opportunities.
• Co-founded Midlothian Laboratories with Carl Whatley, growing the company from one product to over two dozen and attained profitability in every year of its operation.
• 22+ years experience in various pharmaceutical divisions of Johnson & Johnson, including Ortho Pharmaceuticals and McNeil Pharmaceuticals.
• Earned B.S. in Marketing form Florida State University

Michael Altman joined Perceptive in 2007 and is a senior analyst on the investment team. His focus is on medical devices, diagnostics,digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Vensun Pharmaceuticals and Vitruvias Therapeutics.

Mr. Schutter is a seasoned executive with over 30 years of experience in the pharmaceutical industry. Mr. Schutter is currently President and Chief Executive Officer of Arbor Pharmaceuticals, a specialty pharmaceutical company focused on the cardiovascular, hospital, and pediatric markets as well as generics through its Wilshire division. He also serves on the board of directors at Arbor. Prior to joining Arbor, Mr. Schutter served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. Mr. Schutter also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Mr. Schutter has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University.

Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997,and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. Mr. Wild currently serves as Chairman of the Board at Arbor Pharmaceuticals, Inc. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.